top of page

Research Projects

Ongoing projects

Investigating the tumor suppressive potential of microRNAs in Oral squamous cell carcinoma

 In India, oral cancer is the leading cancer in males and the sixth most common malignancy in females. However, in spite of many advances in its treatment, the 5-year survival rate for oral cancer has remained unchanged during the last few decades. It is thus imperative to identify novel therapeutic targets for oral cancer. Studies have shown deregulation of microRNA expression and the contribution of microRNAs to the multi-step process of tumorigenesis, either as oncogenes or tumor suppressor genes. In recent years, microRNAs are being used as therapeutic targets in cancers. Given this background, the interested student(s) will identify and investigate the role and function of epigenetically-silenced (tumor suppressor) miRNAs in oral cancer, with an aim to exploit them as therapeutic targets, using a variety of molecular cell biology techniques, including oral tumor samples from patients and preclinical xenograft nude mice model.

Scientist in the Lab
1-s2.0-S1368837520303523-gr2.jpg

Graphic credit : Wendy D'souza

Mir.jpg

Identification of TSC2-regulated protein coding and non-coding RNA genes

Mutations in tumor suppressor TSC1 and TSC2 genes cause an autosomal dominant disorder, tuberous sclerosis complex (TSC). TSC1 and TSC2 proteins interact to form a complex, which negatively regulates mTORC1 in the PI3K-AKT-mTOR pathway, and in turn regulates cell proliferation. This is a well-known cytoplasmic function of these TSC genes. We and others have shown earlier that TSC1/hamartin localizes to the cytoplasm, whereas TSC2/tuberin shows nuclear as well as cytoplasmic localization. To elucidate the nuclear function of TSC2, we have used gene expression profiling of TSC2-overexpressing cells, luciferase reporter assay, siRNA knockdown, ChIP and EMSA techniques, and have shown for the first time that TSC2 also functions as a transcription factor and transcriptionally regulates Epiregulin, a ligand for EGFR. However, Epiregulin cannot be the only TSC2-regulated gene. Then, what are the other genes regulated by TSC2? The interested student(s) will thus explore and identify other (protein coding, microRNA and long non-coding RNA) genes, which are transcriptionally regulated by TSC2, using a variety of molecular and cell biology approaches such as microRNA microarray analysis and RNA Seq.

Embryonic Stem Cells

Graphic credit : M. Karthik

11010_2021_4088_Fig2_HTML (1).webp

Exploring the mutational profile of Lung Cancer and Hepatocellular carcinoma to identify the genomic landscape and potential for personalized therapy

To assess the mutational landscape and identify genetic mutations for clinical use in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) diagnosis and treatment. The whole-exome sequencing-based assay could be a comprehensive and efficient strategy that complements tissue analysis and expands the scope of personalized targeted therapies for advanced NSCLC and HCC.

     

                                                                 

Closeup of a Petri Dish

Molecular consequences of mutations in ATP7B, coding for a copper transporter:

 Wilson disease (WD) is an autosomal recessive disorder, characterized by excessive deposition of copper in various parts of the body, mainly in the liver and brain. It is caused by mutations in ATP7B, which codes for a trans-Golgi network residing copper transporter. We have recently performed the genetic analysis of 102 WD families from a south Indian population, and identified 36 different ATP7B mutations, including 13 novel ones. However, the molecular consequences of these mutations in disease pathology are not known. Using a variety of molecular and cell biology approaches, the interested student(s) will explore and identify the role of these novel ATP7B mutations in disease pathology. The work will also involve the use of specific inhibitor(s) to restore the function of mutated ATP7B, with an aim to develop therapeutic treatment for WD.

Molecule
bottom of page